GlassScriptPhysician profile
Kushal Naha
NPI 1639586506
$6,535.08
in general payments reported to CMS, 2019-2025
37 companies · $470 in 2025
The $470 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.38 · 2021: $439 · 2022: $761 · 2023: $696 · 2024: $4,100 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,805 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,700 · Food and Beverage: $1,560 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,804.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,700.00 |
| Food and Beverage | $1,560.05 |
| Education | $200.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Molecular Systems, INC. | $3,504.58 | 2024 | |
| Genzyme Corporation | $297.67 | 2021-2024 | |
| Incyte Corporation | $291.42 | 2021-2024 | Jakafi |
| Aveo Pharmaceuticals, INC. | $204.91 | 2023-2025 | Fotivda |
| Pfizer INC. | $198.31 | 2019-2024 | |
| Dendreon Pharmaceuticals LLC | $152.98 | 2022-2023 | Provenge |
| Histosonics, INC. | $150.28 | 2025 | |
| Seagen INC. | $141.93 | 2021-2023 | Padcev |
| Blueprint Medicines Corporation | $127.57 | 2022 | |
| Jazz Pharmaceuticals INC. | $126.64 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.08 | 2023 | Livtencity |
| Eisai INC. | $118.20 | 2022 | |
| Cti Biopharma Corp. | $118.05 | 2022 | |
| Adc Therapeutics America, INC. | $100.50 | 2023 | |
| Novocure INC. | $87.54 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $84.26 | 2022 | |
| Epizyme, INC. | $84.22 | 2021 | |
| Roche Diagnostics Corporation | $64.82 | 2024 | |
| Puma Biotechnology, INC. | $64.79 | 2022 | |
| Janssen Biotech, INC. | $47.11 | 2023-2025 | Rybrevant, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $45.10 | 2025 | Opdivo |
| Genentech USA, INC. | $43.23 | 2019 | |
| Astellas Pharma Global Development | $38.30 | 2025 | Padcev, Vyloy |
| Astellas Pharma US INC | $35.36 | 2024 | |
| Caris Mpi, INC. | $34.02 | 2025 | Mi Cancer Seek |
| Ipsen Biopharmaceuticals, INC | $32.60 | 2024 | Onivyde |
| Genmab U.S., INC. | $29.26 | 2024 | Tivdak |
| Beigene USA, INC. | $23.60 | 2023 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $23.33 | 2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $21.96 | 2025 | |
| Servier Pharmaceuticals LLC | $20.40 | 2023 | |
| Exelixis INC. | $19.98 | 2023 | |
| Acrotech Biopharma INC. | $19.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.69 | 2025 | Imfinzi |
| Ferring Pharmaceuticals INC. | $17.13 | 2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $14.78 | 2019 | |
| Emd Serono, INC. | $13.59 | 2023 | Bavencio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kushal Naha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.